Novo Nordisk Faces Market Share Loss, Forecast Cuts Amid US Demand Weakness

Novo Nordisk is facing significant challenges in 2025, including a downward revision of its earnings expectations driven by weakening demand in the U.S. and intensified competition from Eli Lilly in the weight-loss drug market. The company recently appointed Mike Doustdar as its new CEO, who will need to navigate these market pressures and production capacity constraints amid political risks like potential U.S.-EU pharmaceutical tariffs. These tariffs could disrupt supply chains and R&D efforts, impacting patient access and growth strategies. Investors have reacted negatively, with Novo Nordisk shares plunging over 20%, and analysts expressing concerns about the late-stage pipeline and competitive environment. Despite these issues, some financial analyses project a strong potential upside for the stock, with GuruFocus forecasting more than 200% growth over the next year and the stock holding an "Outperform" rating from multiple brokerages. The evolving market dynamics and company performance remain critical for both the pharmaceutical industry and the Danish economy, given Novo Nordisk's historical significance as Europe's most valuable listed company.